Massamba N, Dirani A, Knoeri J, Pasquier B, Ingram A, Soubrane G
Department of Ophthalmology, Cergy Pontoise Hospital, Paris, France.
Department of Ophthalmology, CHUV, Lausanne, Switzerland.
Eye (Lond). 2015 Nov;29(11):1453-7. doi: 10.1038/eye.2015.128. Epub 2015 Jul 24.
To evaluate the impact of traditional French summer vacation on visual acuity and spectral domain-optical coherence tomography (SD-OCT) of Wet AMD patients being treated with intravitreal Ranibizumab.
This was a consecutive, comparative, single-centre, prospective analysis. All patients who were being treated with intravitreal injection of 0.5 mg ranibizumab at Cergy Pontoise Hospital, Department of Ophthalmology between July 2013 and September 2014 were included. Patients were divided into two groups: (A) patients who skipped one ranibizumab intravitreal injection during holidays, and (B) patients who received injection during their holidays. Evaluations occurred prior to traditional holiday (baseline) and 2 months later, consisting of BCVA using ETDRS, and a complete ophthalmic examination that included slit-lamp biomicroscopy, fundus examination, fluorescein angiography (FA), indocyanine green angiography (ICGA), and spectral domain-optical coherence tomography (SD-OCT). All patients were being treated with PRN anti-VEGF regimen and criteria for reinjection included a visual acuity loss >5 ETDRS letters and/or an increase of central retinal thickness, presence of subretinal fluid, intraretinal fluid, or pigment epithelium detachment. If reinjection criteria were not met, patients were advised to return in 4 weeks.
The mean visual acuity change was -0.071 ± 0.149 (LogMAR) in group A and + 0.003 ± 0.178 in group B (P = 0.041). At the second visit (2 months after preholidays visit), 61.8% of patients in group A had SRF and/or intraretinal cysts, and only 27.6% of patients in group B. There was a significant difference in the persistence of fluid between the two groups (P = 0.007, χ(2)-test).
This cases series demonstrated the detrimental impact of holidays on visual acuity in patients treated with ranibizumab for AMD, which, in spite of their treatment regimen, still leave in vacation. Therefore, it is important to convey the message of treatment adherence to patients, despite their need of holidays.
评估传统法国夏季度假对接受玻璃体内注射兰尼单抗治疗的湿性年龄相关性黄斑变性(Wet AMD)患者视力及光谱域光学相干断层扫描(SD - OCT)的影响。
这是一项连续、对比、单中心的前瞻性分析。纳入2013年7月至2014年9月间在塞尔吉 - 蓬图瓦兹医院眼科接受0.5毫克兰尼单抗玻璃体内注射治疗的所有患者。患者分为两组:(A)假期期间跳过一次兰尼单抗玻璃体内注射的患者,以及(B)假期期间接受注射的患者。评估在传统假期前(基线)及2个月后进行,包括使用ETDRS的最佳矫正视力(BCVA),以及包括裂隙灯生物显微镜检查、眼底检查、荧光素血管造影(FA)、吲哚菁绿血管造影(ICGA)和光谱域光学相干断层扫描(SD - OCT)的完整眼科检查。所有患者均接受按需抗血管内皮生长因子(anti - VEGF)治疗方案,再次注射的标准包括视力下降>5个ETDRS字母和/或中心视网膜厚度增加、存在视网膜下液、视网膜内液或色素上皮脱离。如果未达到再次注射标准,建议患者4周后复诊。
A组平均视力变化为-0.071±0.149(LogMAR),B组为+0.003±0.178(P = 0.041)。在第二次就诊时(假期前就诊后2个月),A组61.8%的患者有视网膜下液(SRF)和/或视网膜内囊肿,而B组仅为27.6%。两组间液体持续存在情况有显著差异(P = 0.007,χ²检验)。
该病例系列证明了假期对接受兰尼单抗治疗AMD患者视力的有害影响,尽管有治疗方案,但患者在度假期间仍会受到影响。因此,尽管患者需要度假,但向他们传达坚持治疗的信息很重要。